Jan Heeres

TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1

Koen Andries, Hilde Azijn, Theo Thielemans, 2004, Antimicrobial Agents and Chemotherapy.

A pharmacophore docking algorithm and its application to the cross‐docking of 18 HIV‐NNRTI's in their binding pockets

Frits Daeyaert, F. Daeyaert, J. Heeres, 2004, Proteins.

Diaryltriazine non-nucleoside reverse transcriptase inhibitors are potent candidates for pre-exposure prophylaxis in the prevention of sexual HIV transmission.

Paul J Lewi, Jurgen Joossens, Koen Augustyns, 2013, The Journal of antimicrobial chemotherapy.

Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1.

Patrick Augustijns, Paul J Lewi, Jurgen Joossens, 2014, Antiviral research.

Structure based activity prediction of HIV-1 reverse transcriptase inhibitors.

Paul J Lewi, H. M. Vinkers, F. Daeyaert, 2005, Journal of medicinal chemistry.

In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).

Stephen H Hughes, Peter Williams, Paul J Lewi, 2005, Journal of medicinal chemistry.